BridgeBio Oncology Therapeutics, Inc. (BBOT)

BBOT Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	1.16	24.62	7.76	0.04	0
Research & Development	-	121.2	73.11	-	-
Total Operating Expenses	1.16	145.82	80.86	0.04	0
Operating Income	-139.89	-145.82	-80.86	-0.04	-0
Interest Income	2.08	11.34	6.38	-	-
Other Non-Operating Income (Expense)	-	0.43	0.21	-	-
Total Non-Operating Income (Expense)	2.08	11.78	6.59	-	-
Pretax Income	-137.81	-134.04	-74.28	-0.04	-0
Net Income	-137.81	-134.04	-74.28	-0.04	-0
Net Income to Common	0.92	-134.04	-74.28	-0.04	-0
Net Income Growth	-58.49%	-	-	-	-
Shares Outstanding (Basic)	36	31	31	4	4
Shares Outstanding (Diluted)	36	31	31	4	4
Shares Change (YoY)	639.23%	-	730.53%	-	-
EPS (Basic)	-524.91	-4.30	-5756.41	-0.01	-
EPS (Diluted)	-524.91	-4.30	-5756.41	-0.01	-
Free Cash Flow	-130.21	-114.5	-55.08	0	0
Free Cash Flow Per Share	-3.64	-3.68	-1.77	-	-
EBITDA	-139.89	-145.21	-80.66	-0.04	-0
EBIT	-139.89	-145.82	-80.86	-0.04	-0

Data Source: Fiscal.ai Last updated: May 12, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 22, 2026

Data Sources Report a data error